MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus
Shots:
- The US NIH to provide vaccine candidates and related material to Medigen Vaccine Biologic (MVC) to initiate the preclinical development of a vaccine for Covid-19 in Taiwan
- The results from a preclinical study will be used to assess the possibility of applying it to clinical testing on humans and developing a new generation of vaccines
- The collaboration marks the second collaboration b/w MVC and NIH since 2015- earlier collaborated to develop a vaccine against dengue fever. Additionally- on Feb 12- 2020- MVC has applied for permission to Taiwan FDA for its RT-PCR tests kit- developed to target corona virus
Click here to read full press release/ article | Ref: The Star | Image: Sequencing
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com